Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Cleveland Clinic

Sites in Cleveland, OH

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 2:59 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1315
Shown on this page
12
Current sort
Recently updated
Campus scope
Cleveland Clinic, Cleveland, OH
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Cleveland Clinic, Cleveland, OH. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 925–936 of 1,315 matching trials with a site at Cleveland Clinic, Cleveland, OH.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting Phase 3 Interventional

A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)

NCT04622319
Site status not listed — check the official record
View directory record Official record
Conditions
HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer
Interventions
DS-8201a, T-DM1
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
1,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
126
States / cities
Anaheim, California • Baldwin Park, California • Bellflower, California + 94 more
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Nov 3, 2026, 2:59 AM EST
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

PATHFINDER 2: A Multi-Cancer Early Detection Study

NCT05155605
Site status not listed — check the official record
View directory record Official record
Conditions
Early Detection of Cancer, Cancer
Interventions
Multi-Cancer Early Detection Test
Device
Lead sponsor
GRAIL, Inc.
Industry
Eligibility
50 Years and older
Enrollment
35,883 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2028
U.S. locations
55
States / cities
Auburn, California • Davis, California • Elk Grove, California + 45 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Nov 3, 2026, 2:59 AM EST
Recruiting Not applicable Interventional

Chronic Nausea and Vomiting in Patients With Normal Gastric Emptying Using the Enterra® Therapy System (NAVIGATE)

NCT06464926
Status at this site: Recruiting
View directory record Official record
Conditions
Nausea, Vomiting
Interventions
Enterra Therapy System
Device
Lead sponsor
Enterra Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
12
States / cities
Scottsdale, Arizona • Los Angeles, California • Newport Beach, California + 9 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Nov 3, 2026, 2:59 AM EST
Recruiting No phase listed Observational

QUELIMMUNE (SCD-PED) PediAtric SurVeillance REgistry

NCT06517810
Status at this site: Recruiting
View directory record Official record
Conditions
Acute Kidney Injury, Acute Kidney Injury Due to Sepsis
Interventions
QUELIMMUNE (SCD-PED)
Device
Lead sponsor
SeaStar Medical
Industry
Eligibility
Up to 22 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
15
States / cities
Birmingham, Alabama • Palo Alto, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Nov 3, 2026, 2:59 AM EST
Active, not recruiting Phase 2 Interventional

Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD

NCT05819359
Site status not listed — check the official record
View directory record Official record
Conditions
Parkinson's Disease
Interventions
BIA 28-6156 10 mg, BIA 28-6156 60 mg, Placebo
Drug
Lead sponsor
Bial R&D Investments, S.A.
Industry
Eligibility
35 Years to 80 Years
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
43
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 30 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Nov 3, 2026, 2:59 AM EST
Recruiting Not applicable Interventional

The GORE VBX FORWARD Clinical Study: A Comparison of the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis to Bare Metal Stenting for Patients With Complex Iliac Occlusive Disease

NCT05811364
Status at this site: Recruiting
View directory record Official record
Conditions
Aortoiliac Occlusive Disease, Peripheral Arterial Disease
Interventions
Stenting of the Common and/or External Iliac Arteries with the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis, Stenting of the Common and/or External Iliac Arteries with Bare Metal Stent
Device
Lead sponsor
W.L.Gore & Associates
Industry
Eligibility
18 Years and older
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
26
States / cities
Little Rock, Arkansas • Long Beach, California • Denver, Colorado + 20 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Nov 3, 2026, 2:59 AM EST
Active, not recruiting Phase 2 Interventional

A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy

NCT06384261
Site status not listed — check the official record
View directory record Official record
Conditions
Leukemia, Myeloid, Acute
Interventions
Cusatuzumab, Venetoclax, Azacitidine
Drug
Lead sponsor
OncoVerity, Inc.
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
20
States / cities
Gilbert, Arizona • Duarte, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Nov 3, 2026, 2:59 AM EST
Recruiting Phase 3 Interventional

Anticoagulation in ICH Survivors for Stroke Prevention and Recovery

NCT03907046
Status at this site: Recruiting
View directory record Official record
Conditions
Intracerebral Hemorrhage, Atrial Fibrillation
Interventions
Apixaban, Aspirin
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
186
States / cities
Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 141 more
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Nov 3, 2026, 2:59 AM EST
Recruiting No phase listed Observational Accepts healthy volunteers

Functional Brain Network Changes in Patients Undergoing Deep Brain Stimulation for Essential Tremor

NCT06293638
Status at this site: Recruiting
View directory record Official record
Conditions
Essential Tremor
Interventions
Alcohol, Alprazolam, Cold Therapy, Peripheral Nerve Stimulation
Drug · Device · Procedure
Lead sponsor
The Cleveland Clinic
Other
Eligibility
30 Years to 80 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Nov 3, 2026, 2:59 AM EST
Recruiting Phase 2 Interventional

Safety, Tolerability and Efficacy Study of ARCT-032 in People With Cystic Fibrosis

NCT06747858
Status at this site: Recruiting
View directory record Official record
Conditions
Cystic Fibrosis, CFTR Gene Mutation
Interventions
ARCT-032
Biological
Lead sponsor
Arcturus Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
13
States / cities
Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Nov 3, 2026, 2:59 AM EST
Active, not recruiting Phase 3 Interventional Results available

Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer

NCT01368588
Site status not listed — check the official record
View directory record Official record
Conditions
Prostate Cancer
Interventions
three-dimensional conformal radiotherapy, intensity modulated radiotherapy, Brachytherapy, Anti-androgen, luteinizing hormone-releasing hormone (LHRH) agonist or antagonist
Radiation · Drug
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older · Male only
Enrollment
2,590 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2031
U.S. locations
454
States / cities
Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 351 more
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Nov 3, 2026, 2:59 AM EST
Recruiting Phase 2 Interventional

Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment

NCT05363280
Status at this site: Recruiting
View directory record Official record
Conditions
Small Cell Lung Cancer, Renal Cell Carcinoma (RCC), Non-Small Cell Lung
Interventions
AL8326 40 mg, AL8326 60 mg, AL8326 80 mg--stopped
Drug
Lead sponsor
Advenchen Pharmaceuticals, LLC.
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
5
States / cities
Birmingham, Alabama • Weston, Florida • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Nov 3, 2026, 2:59 AM EST

About this Cleveland Clinic institution page

What this page lists
ClinicalTrials.gov records that list Cleveland Clinic in Cleveland, OH as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.